Competing interest
ONCOLOGY
James Chih-Hsin Yang reports grants and/or personal fees and/or other from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Eli Lilly, Merck KGaA, Merck Sharp & Dohme, Novartis, Ono Pharmaceuticals, Pfizer, Roche/Genentech, Takeda Oncology, Yuhan Pharmaceuticals, JNJ, Glaxo, Puma Technology, outside the submitted work; Wu-Chou Su reports consulting fees from Bayer, MSD, Merck, Lilly and Roche; Chao-Hua Chiu reports honoraria from AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Roche, and Takeda; Her-Shyong Shiah reports no conflicts of interest; Kang-Yun Lee reports support from Daiichi Sankyo as a principal investigator for conducting the clinical trial; Te-Chun Hsia reports no conflicts of interest; Makiko Uno is an employee of Daiichi Sankyo; Nigel Crawford reports no conflicts of interest; Hiroshi Terakawa is an employee of Daiichi Sankyo; Wen-Chi Chen reports no conflicts of interest; Gensuke Takayama is an employee of, and owns stock in, Daiichi Sankyo; Ching Hsu is an employee of, and owns stock in, Daiichi Sankyo; Ying Hong is an employee of, and owns stock in, Daiichi Sankyo; Carline Saintilien is an employee of, and owns stock in, Daiichi Sankyo; Joseph McGill reports fees from Daiichi Sankyo for consulting as a clinical safety physician; Gee-Chen Chang reports honoraria from F. Hoffmann–La Roche, Ltd, Eli Lilly and Company Oncology, AstraZeneca, Pfizer, Boehringer-Ingelheim, Bristol-Myers Squibb, and Merck Sharp & Dohme.